Bone Historical Income Statement
| BBLG Stock | USD 1.31 0.06 4.80% |
Historical analysis of Bone Biologics income statement accounts such as Ebitda of 503.6 K, Total Operating Expenses of 4.7 M or Gross Profit of 0.0 can show how well Bone Biologics Corp performed in making a profits. Evaluating Bone Biologics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Bone Biologics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Bone Biologics Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bone Biologics Corp is a good buy for the upcoming year.
Bone |
About Bone Income Statement Analysis
Bone Biologics Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Bone Biologics shareholders. The income statement also shows Bone investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Bone Biologics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Bone Biologics Corp. It is also known as Bone Biologics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Bone Biologics Corp minus its cost of goods sold. It is profit before Bone Biologics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from Bone Biologics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Bone Biologics' Depreciation And Amortization is most likely to increase significantly in the upcoming years. The Bone Biologics' current Research Development is estimated to increase to about 7.3 M, while EBIT is forecasted to increase to (8.5 M).
Bone Biologics income statement Correlations
Click cells to compare fundamentals
Bone Biologics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bone Biologics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Operating Expenses | 2.4M | 825.0K | 1.1M | 3.7M | 9.4M | 9.9M | |
| Operating Income | (2.4M) | (825.0K) | (1.1M) | (3.7M) | (9.4M) | (9.0M) | |
| Ebit | (2.4M) | (825.0K) | (1.1M) | (3.7M) | (8.9M) | (8.5M) | |
| Ebitda | (2.4M) | (825.0K) | (804.0K) | (4.4M) | 479.6K | 503.6K | |
| Total Operating Expenses | 2.4M | 825.0K | 1.1M | 3.7M | 9.4M | 4.7M | |
| Income Before Tax | (3.4M) | (1.8M) | (1.6M) | (1.5M) | (8.9M) | (8.5M) | |
| Net Income | (3.4M) | (1.8M) | (1.6M) | 695.9K | (8.9M) | (8.5M) | |
| Depreciation And Amortization | 50.0 | 0.05 | 297.5K | (731.7K) | 9.4M | 9.9M | |
| Selling General Administrative | 1.4M | 484.3K | 1.0M | 2.1M | 2.5M | 2.0M | |
| Research Development | 1.1M | 340.7K | 82.0K | 1.6M | 6.9M | 7.3M | |
| Total Other Income Expense Net | (975.8K) | (998.1K) | (507.6K) | 2.2M | 479.6K | 503.6K | |
| Interest Expense | 975.8K | 998.1K | 805.1K | 2.2M | 2.0M | 1.5M | |
| Net Income From Continuing Ops | (3.4M) | (1.8M) | (1.6M) | (1.5M) | (6.5M) | (6.8M) | |
| Net Income Applicable To Common Shares | (4.4M) | (3.4M) | (1.8M) | (1.6M) | (1.9M) | (1.9M) | |
| Tax Provision | 1.6K | 1.7K | 1.6K | 3.2K | 3.7K | 2.1K | |
| Net Interest Income | (975.8K) | (998.1K) | (805.1K) | (731.7K) | (730.2K) | (766.7K) |
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.